Equities analysts expect that MediWound Ltd. (NASDAQ:MDWD) will report ($0.19) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for MediWound’s earnings, with estimates ranging from ($0.20) to ($0.17). MediWound reported earnings of ($0.26) per share during the same quarter last year, which indicates a positive year over year growth rate of 26.9%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that MediWound will report full year earnings of ($0.76) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.70). For the next year, analysts expect that the company will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.85) to ($0.48). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow MediWound.

A number of equities analysts recently commented on MDWD shares. Jefferies Group LLC set a $10.00 target price on MediWound and gave the company a “buy” rating in a report on Friday, August 25th. Cowen and Company started coverage on MediWound in a report on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price for the company. ValuEngine raised MediWound from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. Oppenheimer Holdings, Inc. set a $10.00 price target on MediWound and gave the company a “buy” rating in a research report on Tuesday, October 17th. Finally, Zacks Investment Research raised MediWound from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $9.15.

Hedge funds have recently bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. raised its position in MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after purchasing an additional 342,165 shares in the last quarter. Wells Fargo & Company MN raised its position in MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 8,745 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in MediWound in the 3rd quarter valued at about $1,538,000. Finally, Renaissance Technologies LLC raised its position in MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares in the last quarter. 20.64% of the stock is currently owned by institutional investors.

MediWound (NASDAQ:MDWD) opened at $4.57 on Friday. MediWound has a twelve month low of $4.25 and a twelve month high of $8.25.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect MediWound Ltd. (MDWD) to Post -$0.19 Earnings Per Share” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/11/12/zacks-analysts-expect-mediwound-ltd-mdwd-to-post-0-19-earnings-per-share.html.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.